Cisapride-induced torsades de pointes is a predictable adverse reaction caused by drug accumulation when co-administered with inhibitors of its biotransformation.
Answers are grounded in this paper and cite their sources.
May warrant avoiding cisapride with CYP inhibitors; leaves open confirmation of interaction predictability in larger cohorts.
Two cases of torsades de pointes associated with cisapride are presented, both in association with concomitant drug therapy that inhibits cisapride biotransformation. In one case, plasma cisapride was elevated days after the event, strongly supporting a role for accumulation of the drug in causing the arrhythmia. It is emphasized that these adverse drug reactions are not idiosyncratic, but rather are predictable based on an understanding of the underlying mechanisms.
No takes yet. Share an insight, caveat, or question.
Vítola et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: